From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: MCPP
Chemical Nomenclature
Common names mCPP
Substitutive name meta-Chlorophenylpiperazine
Systematic name 1-(3-chlorophenyl)piperazine
Class Membership
Psychoactive class Stimulant
Chemical class Phenylpiperazine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 15 mg
Light 20 - 50 mg
Common 50 - 120 mg
Strong 120 - 150 mg
Heavy 150 mg +
Onset 20 - 60 minutes
Peak 2 - 4 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Serotonin releasers
Selective serotonin re-uptake inhibitors
Serotonin-norepinephrine reuptake inhibitors

meta-Chlorophenylpiperazine (also known as mCPP) is a stimulant drug of the phenylpiperazine class. It was first synthesized as one in a series of potential novel antihistamines by Thomas H. Wicker Jr. in 1951 as part of his doctoral work at the University of Florida. [1] Unlike many other stimulants like amphetamine, mCPP is generally considered to be unpleasant. mCPP is notable for inducing anxiety[2], and causing migraines and severe headaches.[3] mCPP is occasionally encountered as an adulterant in street MDMA.[4]



This chemistry section is incomplete.

You can help by adding to it.

mCPP is a drug in the phenylpiperazine class. On the meta-position of the phenyl group, there is a chlorine atom.


mCPP acts as an agonist at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3 and 5-HT7 receptors, as well as inhibiting the serotonin transporter.[5]. Substances that act at the 5-HT2B receptor, most notably fenfluramine, can cause significant heart problems which can be fatal in some individuals.[6] mCPP's action at the 5-HT2A receptor may explain its psychedelic-like effects.

mCPP is an active metabolite of the antidepressant trazodone.[7]

Subjective effects

Disclaimer: The effects listed below are cited from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Cognitive effects

Visual effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

mCPP is not known to be addictive, but there are not any studies exclusively on its addiction potential.

Dangerous interactions

mCPP is metabolized by cytochrome P450 2D6[8], and concurrently taking inhibitors of that enzyme results in increased serum levels of mCPP. Commonly encounter inhibitors of CYP2D6 include ciprofloxacin, bupropion (Wellbutrin), fluoxetine (Prozac) and grapefruit juice.[9]

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • MDMA - The neurotoxic effects of MDMA may be increased when combined with other amphetamines.
  • Cocaine - This combination may increase strain on the heart.
  • Stimulants - MCPP can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
  • 25x-NBOMe & 25x-NBOH - Members of the 25x family are highly stimulating and physically straining. Combinations with stimulants should be avoided due to the risk of excessive stimulation. This can result in panic attacks, thought loops, seizures, increased blood pressure, vasoconstriction, and heart failure in extreme cases.
  • Alcohol - Alcohol can be dangerous to combine with stimulants due to the risk of accidental over-intoxication. Stimulants mask the sedative effects of alcohol, which is the main factor people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects of alcohol are left unopposed, which can result in blackouts and respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be strictly avoided due to DXM's effects on serotonin and dopamine reuptake. This can lead to panic attacks, hypertensive crisis, or serotonin syndrome.
  • MXE - Combinations with MXE may dangerously elevate blood pressure and increase the risk of psychosis.
  • Tramadol - Tramadol lowers the seizure threshold.[10] Combinations with stimulants may further increase this risk.

Serotonin syndrome risk

Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.

Legal issues


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Austria: Since January 1, 2012, mCPP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • China: As of October 2015 mCPP is a controlled substance in China.[13]
  • Germany: mCPP is controlled under BtMG Anlage II, making it illegal to manufacture, import, possess, sell, or transfer it without a license.[14]
  • Switzerland: mCPP is illegal in Switzerland.[15]
  • United Kingdom: mCPP is a Class C, Schedule 4 (Part 1) drug in the United Kingdom.[16]
  • United States: mCPP is unscheduled in the United States, but could be considered an analogue of benzylpiperazine if it is sold for human consumption.[citation needed]

See also

External links


  1. Wicker, Thomas H. (1951) Derivatives of Piperazine. XII. Synethesis of 1-Arylpiperazines and Amino Acid Derivatives. Retrieved from University of Florida Theses & Dissertations Collection. alphbibnum: 000554269 |
  2. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. |
  3. The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study. |
  4. mCPP: an undesired addition to the ecstasy market |
  5. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. |
  6. Drugs and Valvular Heart Disease |
  7. 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole |;jsessionid=9006CB66248FC2F30E99D5AEAB847661.f04t01
  8. Human CYP2D6 and metabolism of m-chlorophenylpiperazine |
  9. P450 Drug Interaction Table |
  10. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67.
  11. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441.
  12. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441.
  13. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. 
  16. Home Office Controlled Drugs |